A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.
This is a Phase 1, multicenter, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of DCC-3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
Start: May 2021